Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (469)

« Back to Publications

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Turkalj S. et al, (2026), Blood, 147, 613 - 632

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML.

Nier S. et al, (2025), Future Oncol, 21, 3713 - 3719

LIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia.

Vyas P. et al, (2025), Future Oncol, 21, 3721 - 3729

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome.

Elliott N. et al, (2025), Blood, 146, 1561 - 1574

Genome-wide association study of somatic GATA1s mutations in newborns with Down syndrome.

Li Y. et al, (2025), Blood Adv, 9, 4235 - 4243

evised prognostic model for patients with acute myeloid leukemia and first relapse.

van der Maas NG. et al, (2025), Blood Adv, 9, 3853 - 3864

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.

Daver N. et al, (2025), Blood, 146, 601 - 611

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Zeidner JF. et al, (2025), Blood, 146, 590 - 600

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Detecting and quantifying clonal selection in somatic stem cells.

Körber V. et al, (2025), Nat Genet, 57, 1718 - 1729

Clonal tracing with somatic epimutations reveals dynamics of blood ageing.

Scherer M. et al, (2025), Nature, 643, 478 - 487

Protocol for high-quality RNA sequencing, cell surface protein analysis, and genotyping in single cells using TARGET-seq.

Jakobsen NA. et al, (2025), STAR Protoc, 6

Load More

1
2
3
4
5
6
7
...
»